Enzo Biochem, Inc. (ENZ) Downgraded by BidaskClub

BidaskClub downgraded shares of Enzo Biochem, Inc. (NYSE:ENZ) from a hold rating to a sell rating in a research note published on Monday morning.

Separately, Zacks Investment Research cut Enzo Biochem from a buy rating to a hold rating in a research report on Tuesday, May 16th.

Shares of Enzo Biochem (ENZ) opened at 11.00 on Monday. Enzo Biochem has a one year low of $4.88 and a one year high of $12.04. The firm’s 50-day moving average is $11.25 and its 200-day moving average is $9.07. The stock has a market capitalization of $510.48 million, a price-to-earnings ratio of 15.43 and a beta of 0.97.

WARNING: This article was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.com-unik.info/2017/08/18/enzo-biochem-inc-enz-downgraded-by-bidaskclub.html.

Several hedge funds have recently bought and sold shares of ENZ. Evermore Global Advisors LLC boosted its stake in shares of Enzo Biochem by 7.3% in the second quarter. Evermore Global Advisors LLC now owns 3,555,233 shares of the medical research company’s stock valued at $39,250,000 after buying an additional 242,441 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Enzo Biochem by 10.5% in the second quarter. Dimensional Fund Advisors LP now owns 2,026,647 shares of the medical research company’s stock valued at $22,376,000 after buying an additional 193,246 shares during the last quarter. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Enzo Biochem by 20.3% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 999,961 shares of the medical research company’s stock valued at $11,040,000 after buying an additional 168,607 shares during the last quarter. TIAA CREF Investment Management LLC boosted its stake in shares of Enzo Biochem by 43.9% in the second quarter. TIAA CREF Investment Management LLC now owns 533,923 shares of the medical research company’s stock valued at $5,895,000 after buying an additional 162,854 shares during the last quarter. Finally, Millrace Asset Group Inc. purchased a new stake in shares of Enzo Biochem during the first quarter valued at approximately $1,256,000. Institutional investors and hedge funds own 62.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

What are top analysts saying about Enzo Biochem Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Enzo Biochem Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit